Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Brunswick – page 4

88 clinical trials in Brunswick, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Brunswick at a glance
88
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

88 trials in Brunswick

Open in trial search

Ewing's sarcoma

Recruiting

Study on Ewing Sarcoma Treatment with Vinorelbine and Drug Combination for Patients with Primary and Disseminated Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:GPOH gGmbH

Pancreaticoduodenectomy

Recruiting

Study on Nicotine Patch for Preventing Delayed Gastric Emptying in Patients After Pancreatoduodenectomy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nicotine
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Acute myeloid leukaemia

Recruiting

Study on Decitabine, Venetoclax, and Tretinoin for Patients with Acute Myeloid Leukemia Who Cannot Have Induction Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Medical Center - University Of Freiburg

Breast cancer+2

Recruiting

Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:WSG Women's Cancer Study Group GmbH

Triple negative breast cancer

Recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gilead Sciences Inc.

Chronic kidney disease

Not yet recruiting

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Not yet recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Acute lymphocytic leukaemia

Not yet recruiting

Study of blinatumomab plus drug combination in children and adolescents with acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:GPOH gGmbH

Acute myeloid leukaemia+1

Not yet recruiting

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:GPOH gGmbH

Chronic kidney disease

Not recruiting

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Interstitial lung disease+1

Not recruiting

Study to Test if Nerandomilast (BI 1015550) Helps Patients with Interstitial Lung Disease Related to Rheumatic Diseases

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Brunswick

What the registry says about research in the country

01 Hematologic Oncology

Innovative clinical trials focusing on Acute Myeloid Leukemia (AML) and lymphoblastic disorders, testing novel combination therapies and targeted treatments for patients with various genetic mutations.

  • Treatment-resistant leukemia therapies
  • Gene-targeted interventions
  • Pediatric blood cancers

Studies evaluate both newly diagnosed cases and those not eligible for intensive chemotherapy.

02 Solid Tumors

Comprehensive research into prostate cancer and bladder cancer treatments, with particular focus on innovative hormone therapies and immunotherapy approaches.

  • Metastatic disease management
  • Hormone-sensitive cancers
  • Targeted therapies

Multiple trials exploring combination treatments and novel therapeutic approaches for various stages of disease.

03 Respiratory Medicine

Advanced research in non-small cell lung cancer and interstitial lung diseases, investigating new immunotherapy combinations and targeted treatments.

  • First-line treatments
  • Combination therapies
  • Autoimmune-related lung conditions

Studies focus on improving survival rates and treatment outcomes for both early-stage and metastatic disease.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.